

FORM 11

NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: AI/ML Innovations Inc. (the "Issuer").

Trading Symbol: AIML

Date: July 15, 2021

1. **New Options Granted:**

Date of Grant: July 15, 2021

Name of Optionee	Position (Director/ Officer/ Employee/ Consultant/ Management Company	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
Octagon Media Corp	Consultant	No	350,000	0.70	14/01/2022	Nil
Volt Strategic Partners Ltd.	Consultant	No	50,000	0.80	05/07/2023	Nil
Venture Liquidity Providers Inc.	Consultant	No	50,000	0.80	05/07/2023	Nil
1022 Consulting	Consultant	No	100,000	0.80	15/07/2022	Nil
Blake Fallis	Consultant	No	200,000	0.80	15/07/2023	Nil

Total Number of optioned shares proposed for acceptance: 750,000.

2. Other Presently Outstanding Options:

Name of Optionee	No. of Optioned Shares ⁽¹⁾	Exercise Price	Original Date of Grant	Expiry Date
Randy Duguay	500,000	0.25	30/12/2020	30/12/2022
Bruce Matichuk	500,000	0.25	30/12/2020	30/12/2022
Nick Watters	300,000	0.40	11/01/2021	30/09/2021
Todd Violette	400,000	0.40	11/01/2021	30/09/2021
Sue Knutsen	200,000	0.40	11/01/2021	30/09/2021

(1) Set out number of optioned shares for each grant with different terms.

3. Additional Information

- (a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held. April 27, 2021
- (b) State the date of the news release announcing the grant of options. N/A
- (c) State the total issued and outstanding share capital at the date of grant or amendment. 29,081,672 shares
- (d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options. 9.1%
- (e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan. 258,167
- (f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors. N/A
- (g) Describe the particulars of any proposed material changes in the affairs of the Issuer.

The Issuer is in the process of completing a definitive agreement further to the terms of a binding Letter of Intent which was announced June 28, 2021. The LOI stated that the Issuer is to acquire a 70% undivided interest in the

North American rights to all of Tech2Health's products and brands, in addition to a 22.22% equity interest in Tech2Health's global operations, subject to completion of due diligence.

4. Certificate of Compliance


The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated July 15, 2021.

Tim Daniels

Name of Director or Senior
Officer



Signature

Director

Official Capacity